Appendix C

IRB Form

UNIVERSITY OF SOUTH ALABAMA

COLLEGE OF MEDICINE

INSTITUTIONAL REVIEW BOARD

Renewal Review

Protocol #: 05-167
Principal Inv: Labbe-Goldsmith, Elise, Ph.D.
Title: EVALUATING ANGER AND RESILIENCY IN RELATION TO RACIAL STEREOTYPES DURING STRESS

Review Date: 7/13/2006
Type: EXPEDITED
Renewal Date: 08/01/2006
Renewal Expiration: 07/31/2007
Status: ACTIVE

This panel, operating under the authority of the DHHS Office for Human Research and Protection, assurance number FWA 00001602, has reviewed the following items:

1.) Protection of the rights and the welfare of human subjects involved.
2.) The methods used to secure and the appropriateness of informed consent.
3.) The risk and potential benefits to the subject.

On the basis of this review, we recommend:

<table>
<thead>
<tr>
<th>Board Action</th>
<th>Cause for Review</th>
</tr>
</thead>
<tbody>
<tr>
<td>(χ ) Approval</td>
<td>( ) Renewal</td>
</tr>
<tr>
<td>( ) Deferral</td>
<td>( ) Other (See Notes)</td>
</tr>
<tr>
<td>( ) Reexamination</td>
<td></td>
</tr>
</tbody>
</table>

for the protocol and consent in terms of the University of South Alabama's statement of policy and procedure concerning the use of human subjects in the investigation.

The regulations require that the investigator not initiate any changes in the research without prior IRB approval, except where necessary to eliminate immediate hazards to the human subjects, and that all problems involving risks and adverse events be reported to the IRB immediately.

Advertisements for recruitment of subjects must receive prior IRB approval. This and subsequent consent forms that have been approved will be certified with an IRB stamp on the last page. You must use copies of the current consent form with the current IRB Approval Stamp unless consent has been waived. All subjects must receive a copy of the current consent form.

NOTES:

- Expedited review for the continuing use of research per category:
  - 46.110 (9) Continuing review of research, not conducted under an investigational new drug application or investigational device exemption where categories two (2) through eight do not apply but the IRB has determined and documented at a convened meeting that the research involves no greater than minimal risk and no additional risks have been identified.

Chair, Institutional Review Board

Date